This article focuses on one of those potential combination therapies: oncolytic viruses (OVs). In the tug-of-war between fire (immune stimulation) and ice (immune suppression), ice usually wins ...

VP-315 is described as a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy that could induce ...

MSLN-targeted oncolytic adenoviruses show promise for systemic therapy of advanced cancers May 6, 2025 Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a ...

Biotech company PsiVac is developing Ixovex-1, the first patented virus with a single base pair mutation able to replicate rapidly, opening potential new treatment options for solid tumors and beyond.

Key advancements in Verrica’s pipeline include positive data from a Phase 2 study of VP-315, an oncolytic peptide candidate targeting basal cell carcinoma. Additionally, the company plans to ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...